Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN trial, demonstrating that orforglipron, an investigational once-daily oral GLP-1 receptor agonist, successfully helped patients maintain weight loss after switching from injectable incretin therapies such as Wegovy (semaglutide) and Zepbound (tirzepatide). The study met all primary and key secondary endpoints at 52 weeks, reinforcing the potential of oral GLP-1 therapy as a long-term weight maintenance option.
Science Significance
The ATTAIN-MAINTAIN trial marks a scientific milestone in obesity pharmacotherapy, as it is the first late-stage study to evaluate direct transition from injectable GLP-1 or dual incretin therapies to an oral GLP-1 small molecule. Orforglipron demonstrated superior weight maintenance versus placebo, with patients switching from Wegovy maintaining all but 0.9 kg of prior weight loss, while those transitioning from Zepbound maintained weight with an average difference of 5.0 kg at one year. The study validates that non-peptide, orally administered GLP-1 receptor agonists can achieve durable metabolic effects comparable to injectables, potentially reshaping long-term obesity management strategies.
Regulatory Significance
From a regulatory perspective, the data strongly support Lilly’s new drug application (NDA) submission to the U.S. Food and Drug Administration for orforglipron in obesity treatment. The trial’s randomized, double-blind, placebo-controlled design, use of efficacy and modified treatment-regimen estimands, and achievement of clearly defined endpoints align with FDA expectations for chronic weight management therapies. Additionally, the drug’s receipt of a Commissioner’s National Priority Voucher underscores its perceived public health relevance and may accelerate regulatory review timelines.
Business Significance
Advertisement
For Lilly, orforglipron represents a strategic expansion of its cardiometabolic franchise, complementing blockbuster injectable brands while addressing limitations related to injections, cold-chain logistics, and adherence. An effective oral GLP-1 therapy could significantly expand market reach, improve patient persistence, and strengthen Lilly’s competitive position amid intensifying rivalry in the obesity drug market. With more than 4,500 participants enrolled across the global ATTAIN Phase 3 program, orforglipron is positioned as a potential next-generation growth driver in one of the fastest-growing pharmaceutical segments.
Patients’ Significance
For patients, especially those struggling with long-term weight maintenance, the findings offer meaningful hope. Obesity is widely recognized as a chronic, relapsing disease, and discontinuation of injectable therapies often leads to weight regain. The ability to switch seamlessly to a once-daily oral therapy without food or water restrictions provides a more convenient, patient-centric option. Importantly, the safety profile of orforglipron was consistent with previous Phase 3 studies, with mostly mild-to-moderate gastrointestinal adverse events and low discontinuation rates, supporting its suitability for long-term use.
Policy Significance
At a policy level, these results may influence future obesity treatment guidelines and reimbursement frameworks by reinforcing obesity as a lifelong disease requiring sustained pharmacologic intervention. Oral GLP-1 therapies like orforglipron could enhance treatment accessibility, reduce healthcare system burdens associated with injectable administration, and support broader public health efforts to address obesity-related comorbidities such as cardiovascular disease, hypertension, and sleep apnea.
Overall, the ATTAIN-MAINTAIN trial positions orforglipron as a potentially transformative oral GLP-1 therapy, capable of sustaining clinically meaningful weight loss after injectable treatment. As Lilly advances toward regulatory review and future scientific disclosures, these findings highlight a significant evolution in obesity drug development, with implications spanning science, regulation, business strategy, patient care, and health policy.
Source: Eli Lilly and Company press release
